Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Quizartinib - Daiichi Sankyo Company

Drug Profile

Quizartinib - Daiichi Sankyo Company

Alternative Names: AC-010220; AC-220; ASP-2689; VANFLYTA

Latest Information Update: 24 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes
  • Discontinued Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 18 Oct 2019 The CHMP of EMA adopts a negative opinion for MAA of quizartinib for treatment of Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater)
  • 18 Oct 2019 Daiichi Sankyo completes enrolment in the phase III Quantum-First trial for Acute myeloid leukaemia (Combination therapy, First-line therapy, Newly-diagnosed, In the elderly) in USA, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Croatia, Czech Republic, France, Germany, Hong Kong, Israel, Italy, Japan, South Korea, Poland, Portugal, Romania, Russia, Serbia, Singapore, Taiwan, Ukraine, Estonia, the United Kingdom, Hungary and Spain (PO)
  • 10 Oct 2019 Launched for Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top